BIOSION ACHIEVEMENTS

Biosion is committed to developing therapies that will have significant impact in treating patients worldwide with immune and oncologic diseases.

Our best-in-class and first-in-class portfolio is designed to address significant unmet medical needs through the development of mono and bi-specific protein therapeutics, antibody drug conjugates and macrophage reprogramming agents

  • 5
    Assets in clinical development
  • 3
    Proprietary technology platforms
  • 10+
    Innovative therapies in preclinical or clinical development
  • 12
    Partnered programs
  • A Diversified Portfolio with Global Vision
  • Patient-centric focus is integral to Biosion’s R&D strategy
  • Portfolio of differentiated biologics to compete on the global stage
RICH PIPELINE OF
BREAKTHROUGH THERAPEUTICS
  • Molecule: BSI-045B
    Modality / Target:
    TSLP
    Severe Asthma
    Partner: CTTQ - China
    • Preclinical
      Phase I
      Phase II
      Phase III
    Atopic Dermatitis
    • Preclinical
      Phase I
      Phase II
      Phase III
    COPD
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-502
    Modality / Target:
    bsAb, targets undisclosed
    Auto-Immune
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-038
    Modality / Target:
    CD40
    Solid Tumors
    Partner: CTTQ - China
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-060T
    Modality / Target:
    Siglec-15
    Solid Tumors
    Partner: PYXIS - Ex China
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-585
    Modality / Target:
    PD1/ILT4
    Solid Tumors
    Partner: Celldex - Ex China
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-04702
    Modality / Target:
    TROP2 ADC
    Solid Tumors
    Partner: OBI - Ex China
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-082
    Modality / Target:
    SIRPα
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-001
    Modality / Target:
    HER2
    Solid Tumors
    Partner: ANKEBIO - China
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-510
    Modality / Target:
    bsAb, targets undisclosed
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-075
    Modality / Target:
    PVRIG
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-500
    Modality / Target:
    bsAb, targets undisclosed
    Solid Tumors
    Partner: CTTQ - China
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-715
    Modality / Target:
    ADC, targets undisclosed
    Solid Tumors
    Partner: ImmunoGen
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-712
    Modality / Target:
    ADC, targets undisclosed
    Solid Tumors
    Partner: ImmunoGen
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-709
    Modality / Target:
    ADC, targets undisclosed
    Solid Tumors
    Partner: ImmunoGen
    • Preclinical
      Phase I
      Phase II
      Phase III
Biosion’s Mission
To discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftsmanship for patients worldwide
Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA
BD@Biosion.com
1-302-998-5126
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号
BIOSION ACHIEVEMENTS

Biosion is committed to developing therapies that will have significant impact in treating patients worldwide with immune and oncologic diseases.

Our best-in-class and first-in-class portfolio is designed to address significant unmet medical needs through the development of mono and bi-specific protein therapeutics, antibody drug conjugates and macrophage reprogramming agents

  • 5
    Assets in clinical development
  • 3
    Proprietary technology platforms
  • 10+
    Innovative therapies in preclinical or clinical development
  • 12
    Partnered programs
  • A Diversified Portfolio with Global Vision
  • Patient-centric focus is integral to Biosion’s R&D strategy
  • Portfolio of differentiated biologics to compete on the global stage
RICH PIPELINE OF BREAKTHROUGH THERAPEUTICS
  • All categories
  • Allergy /immunology
  • Oncology
  • BSI-045B
    Modality / Target:
    TSLP
    Partner
    MORE
    Severe Asthma
    • Preclinical
      Phase I
      Phase II
      Phase III
    CTTQ - China
    Atopic Dermatitis
    • Preclinical
      Phase I
      Phase II
      Phase III
    COPD
    • Preclinical
      Phase I
      Phase II
      Phase III
  • BSI-502
    Modality / Target:
    bsAb, targets undisclosed
    Partner
    MORE
    Auto-Immune
    • Preclinical
      Phase I
      Phase II
      Phase III
  • BSI-038
    Modality / Target:
    CD40
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    CTTQ - China
  • BSI-060T
    Modality / Target:
    Siglec-15
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    PYXIS - Ex China
  • BSI-585
    Modality / Target:
    PD1/ILT4
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    Celldex - Ex China
  • BSI-04702
    Modality / Target:
    TROP2 ADC
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    OBI - Ex China
  • BSI-082
    Modality / Target:
    SIRPα
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • BSI-001
    Modality / Target:
    HER2
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    ANKEBIO - China
  • BSI-510
    Modality / Target:
    bsAb, targets undisclosed
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • BSI-075
    Modality / Target:
    PVRIG
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • BSI-500
    Modality / Target:
    bsAb, targets undisclosed
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    CTTQ - China
  • BSI-715
    Modality / Target:
    ADC, targets undisclosed
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    ImmunoGen
  • BSI-712
    Modality / Target:
    ADC, targets undisclosed
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    ImmunoGen
  • BSI-709
    Modality / Target:
    ADC, targets undisclosed
    Partner
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    ImmunoGen
Biosion’s Mission
To discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftsmanship for patients worldwide
Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA
BD@Biosion.com
1-302-998-5126
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号